Newark, New Castle, USA, May 26, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for recurrent vulvovaginal candidiasis in 2022 to be worth US$ 1.02 billion, and it is expected that it will increase at a revenue CAGR of 4.2% to reach US$ 1.48 billion by 2031.
The global market for recurrent vulvovaginal candidiasis was analyzed and is expected to rise significantly, with a considerable revenue share during the forecast period. Candida albicans is frequently the cause of vulvovaginal candidiasis (VVC). However, other Candida species or yeasts may also be responsible.
Key Takeaways:
- The rising prevalence of fungal infections in females is driving the market revenue share.
- The key driver in developing the market is creating a strong product pipeline.
- The increasing antibiotic resistance is increasing the market revenue growth rapidly.
Recent Development in the Recurrent Vulvovaginal Candidiasis Market:
- In December 2022, The FDA approved a second indication for BREXAFEMME® (ibrexafungerp tablets), a biotechnology company that creates novel medications to treat and prevent difficult-to-treat and drug-resistant fungal infections. This second indication is for the prevention of recurrent vaginal candidiasis (RVVC).
Request a Free Sample of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/recurrent-vulvovaginal-candidiasis-market/8832
Recurrent Vulvovaginal Candidiasis Market Scope
| Report Attribute | Details |
| Market Size Value in 2022 | US$ 1.02 billion |
| Revenue Forecast in 2031 | US$ 1.48 billion |
| CAGR | 4.2% |
| Base Year for Estimation | 2022 |
| Forecast Period | 2023 to 2031 |
| Historical Year | 2021 |
| Segments Covered | Type, End User, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Competitive Landscape
A list of the prominent players operating in the global market for recurrent vulvovaginal candidiasis includes:
- Mycovia Pharmaceuticals, Inc.
- Basilea Pharmaceutica Ltd.
- Pacgen Life Science Corporation
- Scynexis, Inc.
- Grupo Ferrer Internacional S.A.
Market Drivers and Restraints:
The global recurrent vulvovaginal candidiasis market revenue is driven by the high prevalence of RVVC, growing awareness about RVVC among women, and the development of novel therapies, such as topical antifungal agents and probiotics.
Market Segmentation:
Segmentation By Drug Class
Based on the drug class, the azole segment dominates the global recurrent vulvovaginal candidiasis market with the largest revenue share as it is the first line of treatment usually recommended for uncomplicated RVVC.
Segmentation By Route of Administration
Based on the route of administration, the oral segment dominates the global recurrent vulvovaginal candidiasis market with the largest revenue share. It is expected that it will maintain its share during the forecast period due to the widely used simple administration method for azoles, excellent absorption, and use of antifungal drugs.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/recurrent-vulvovaginal-candidiasis-market/8832
Segmentation By Distribution Channel
Based on the distribution channel, the retail pharmacy segment accounts for a sizable revenue share in the global recurrent vulvovaginal candidiasis market due to the market's availability of both prescription and over-the-counter medications; retail pharmacists are essential in providing patients with advice and earning their trust.
Regional Growth Dynamics
Based on the region, North America, with the largest revenue share, dominates the global recurrent vulvovaginal candidiasis market. This large revenue share is attributed to the region's well-established healthcare systems, high rates of disease, and presence of important manufacturers.
Report Coverage
Growth Plus Reports analyzed the global market for recurrent vulvovaginal candidiasis in-depth. We studied the fundamental market characteristics, significant investment sectors, regional growth analytics, revenue estimates, competing market players, and mergers and acquisitions.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecast Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL RECURRENT VULVOVAGINAL CANDIDIASIS MARKET- ANALYSIS & FORECAST, BY DRUG CLASS
- Azoles
- Antibiotics
- Allylamines
- Others
- GLOBAL RECURRENT VULVOVAGINAL CANDIDIASIS MARKET- ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
- Oral
- Intravenous
- Topical
- GLOBAL RECURRENT VULVOVAGINAL CANDIDIASIS MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
RECURRENT VULVOVAGINAL CANDIDIASIS MARKET TOC
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8832
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse more latest healthcare reports:
Retrovirus Testing Market by Test Type (Antibody Test, Antigen/Antibody Test), Technique Type (ELISA, PCR), Sample Type (Serum, Blood) – Global Outlook & Forecast 2023-2031
Southern Blotting Market by Products (Consumables and Instruments), Application (Medical Diagnosis, Genetic Fingerprinting, Scientific Research), End User (Biotechnology & Pharmaceutical Industries, Research Institutes) - Global Outlook and Forecast 2023-2031
Laser Indirect Opthalmoscope Market by Laser Type (Photocoagulating Laser Indirect Ophthalmoscope, Photo Disrupting Laser Indirect Ophthalmoscope), Therapeutic Application (Diabetic Retinopathy, Lattice Degeneration), End User (Ophthalmic Clinics, Multispecialty Hospitals) – Global Outlook & Forecast 2023-2031
AI in Endoscopy Market by Application (Bronchoscopy, Gastrointestinal Endoscopy), Component (Hardware, Software), End User (Hospitals, Ambulatory Care Centers) – Global Outlook & Forecast 2023-2031
Recording Chart Papers Market by Type (Ultrasound / OBGYN Recording Chart Papers, Fetal Monitoring Recording Chart Papers), End User (Hospitals & Clinics, Diagnostic Centers) - Global Outlook & Forecast 2023-2031
Unleashing the Power of Innovation in Med Tech https://growthplusmedtechroundup.com/
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
